Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Acute 3beta-Thalassemia 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hodgkin Disease 2Hematologic Neoplasms 2Thalassemia 1Primary Myelofibrosis 1Neurofibromatosis 1 1Neoplasm, Residual 1Multiple Myeloma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Large Granular Lymphocytic 1Leukemia 1Influenza, Human 1Chromosome Aberrations 1Chromosome 7, monosomy 1Anemia, Sickle Cell 1Anemia, Refractory, with Excess of Blasts 1

Interventions

thymoglobulin 1ruxolitinib 1fludarabine 1Tacrolimus 1Rituximab 1Panobinostat 1Mycophenolic Acid 1Dexamethasone 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thalassemia × thymoglobulin × 90 days × Clear all
NCT05736419 2026-06-03

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡